Life sciences automation company Automata has raised £37 million in Series B funding.

This investment comes on the back of rapid growth for Automata, whose focus on the life sciences has seen nearly a million tests conducted by scientists and clinicians in recent months.

It will enable significant development, in the UK and beyond, of Automata Labs for scientists working across diagnostic, drug discovery and BioTech.

The firm says its technology enables life scientists to shorten turnaround times by scaling capacities, and spend more time on their analyses – which also leads to cost reductions.

Automata’s systems have been successfully utilised by NHS pathology labs to help them meet diagnostic backlogs and upscale capacity. In one of these labs they are running 40 fully automated stations 24/7.

Automata is also currently advising and deploying automation with contract research organisations, research labs and leading blue chip healthcare institutions.

The round was led by Octopus Ventures with participation from returning investors Hummingbird, Latitude Ventures, ABB Technology Ventures, Isomer Capital as well as strategic investors such as In-Q-Tel, amongst others.

“I’m really excited at how this funding will take us on the next stage of our successful journey,” said Mostafa ElSayed, CEO. 

“At Automata we have always believed in the power of automation to support a variety of uses especially when deployed at scale. We are thrilled to see our users adopt automation at a scale that transforms their ability to deliver more innovation in the life sciences to ultimately accelerate their pursuit of progress. 

“For far too long scientists and clinicians have been having to work with overly complex lab solutions: equipment and software are disjointed and difficult to orchestrate, while solutions are often too rigid and inappropriate for labs with small geographic footprints.  Our next generation technology solves this.”

The key to commercialising a medical device

Jess McCreadie, principal, HealthTech at Octopus Ventures, said: “Automata’s robotic capabilities are truly the first of its kind and the company has combined this with deep expertise in automation and a highly effective business model which has created a leading-edge over competitors. 

“Automata Labs accelerates human ingenuity, empowering labs, and scientists, to achieve consistent results faster, on a greater scale, and to ultimately upscale their ambitions.

“We are delighted to have led this financing round as Automata represented exactly the type of highly innovative company we invest in and support. We are excited for Automata’s next steps, both within the life sciences industry, and beyond.”

‘We went through nearly 90 prototypes to get to our final design’